GeoVax Labs, Inc. ($GOVX), a biotechnology company focused on developing groundbreaking therapies and vaccines for cancers and numerous infectious diseases, is pleased to announce the achievement of significant milestones in its three ongoing clinical stage trials for COVID-19 vaccines and late-stage head and neck cancer treatment.
The company has successfully met the enrollment target for its Phase 2 clinical trial, which evaluates GEO-CM04S1 as a COVID-19 vaccine booster for healthy patients who have previously received the Pfizer or Moderna mRNA vaccine. This milestone is a testament to GeoVax's relentless pursuit of developing a next-generation COVID-19 vaccine that induces both antibody and T cell responses to parts of the virus less likely to mutate over time.
Chairman and CEO, David Dodd, expressed his gratitude to all those who played a part in reaching this crucial milestone. He firmly believes that GEO-CM04S1 may offer a more robust and durable degree of protection than the current authorized COVID-19 vaccines. It serves not only as a booster to the authorized mRNA vaccines but also is in a clinical trial as a primary vaccine for highly vulnerable immunocompromised patients.
In addition, GeoVax is making significant strides in its oncology program. The company recently presented Phase 1/2 clinical trial data for its gene therapy candidate, Gedeptin®, at the American Association for Cancer Research (AACR) and the American Head and Neck Society (AHNS) joint Head and Neck Cancer Conference.
GeoVax will present these milestones at BioFuture, an event for innovators, scheduled to take place at the Lotte Hotel in New York City at 3:30 pm on Thursday, October 5th. Investors receive complimentary registration for the event.
The company will also discuss the opportunities of the $5B Project NextGen Covid grants from the U.S. Government. This government funding boosts efforts to tackle the ongoing global health crisis through the development of more effective vaccines, manufacturing and research against future strains of COVID-19.
GeoVax continues to forge ahead with its mission of creating novel therapies and vaccines for some of the world's most threatening infectious diseases and cancers. The company's innovative approach, combined with their robust pipeline, promises exciting developments in the fight against these diseases. Visit the GeoVax website for more information about their ongoing projects and achievements.
For more details about the BioFuture event and registration, please visit the event website https://biofuture.com
Forward-Looking Statements This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements primarily on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our results to differ may emerge from time to time, and it is impossible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
